Auris Medical up 19% ahead of AM-101 trial data

|About: Auris Medical Holding (EARS)|By:, SA News Editor

Thinly traded micro cap Auris Medical Holdings (EARS +19%) heads north on a 6x surge in volume. No particular news accounts for the move, but top-line results from a Phase 3 study assessing lead product candidate AM-101 for the treatment of acute tinnitus (ringing in the ear) are expected this month.

AM-101 contains esketamine hydrochloride, an N-Methyl-D-aspartate (NMDA) receptor antagonist. It is administered in one treatment cycle consisting of three injections into the middle ear over three to five days. Once injected, the drug diffuses through the round window into the cochlea.

Read now Auris Medical - Near-Term Phase 3 Results And A Major Upside

Update: Slingshot Insights has a proposed project on what to expect from the Phase 3 study. This would be a very timely event.

Subscribe for full text news in your inbox

This was corrected on 08/17/2016 at 12:18 PM. Slingshot Insights has proposed an expert interview to discuss what to expect with the P3 data. Superb timing for interested investors.